China SXT Pharmaceuticals announces $12 million registered direct offering

China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) said on October 8, 2026 that it had signed a definitive agreement with institutional investors to sell 8,000,000 Class A ordinary shares, no par value, or pre-funded warrants in their place, at $1.50 per share in a registered direct offering.¹

Alongside the shares, the company agreed to issue the same investors 8,000,000 warrants with an exercise price of $2.75 per share, immediately exercisable upon issuance and carrying a one-year term.¹ Each warrant also includes a zero cash exercise option allowing the holder to acquire up to 9 Class A shares.¹

The company said gross proceeds from the offering are expected to total approximately $12 million before placement agent fees and other offering expenses.¹ Investors will also have the right to purchase up to an additional $12 million of securities on the same terms within 30 days of closing.¹ Closing is expected on or around October 9, 2026, pending customary conditions.¹

Univest Securities, LLC is serving as the sole placement agent for the deal.¹ The offering is being conducted under a Form F-3 shelf registration statement, file number 333-291428, which the company previously filed with the SEC and which became effective December 1, 2025.¹

A related Form 6-K filed the same day noted a correction to the release: the original press release contained a typographical error on the warrant exercise price, which the company clarified should be $2.75 per Class A ordinary share.¹

China SXT Pharmaceuticals, founded in 2005 and based in Taizhou City, Jiangsu Province, China, develops, manufactures, and markets traditional Chinese medicine pieces, a form of processed traditional Chinese medicine ready for use.¹